Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Asuragen unveils AmplideX FMR1 PCR kit in Europe
The AmplideX FMR1 PCR Kit will help in the diagnosis of fragile X syndrome and associated disorders, and can accurately resolve sample zygosity and detect the full range
The AmplideX FMR1 PCR Kit will help in the diagnosis of fragile X syndrome and associated disorders, and can accurately resolve sample zygosity and detect the full range
Genzyme anticipates a shortage in the US beginning in mid-April and extending through mid-June. According to the European Medicines Agency Genzyme will only be able to reach around
Earlier in 2008, J&JPRD has got license to Isogenica’s CIS display technology, as successor in business to Centocor Research & Development, for application with the J&JPRD’s Centyrin scaffold
Earlier, Ranbaxy has got exclusive rights for selling the drug from Pfizer, under a settlement agreement signed between the companies which provides Ranbaxy with the 180 days of
The prospective randomised Phase 2 trial enrolled 184 patients who were randomised to receive three dose levels of PF-04523655 (0.4mg, 1mg, and 3mg) or laser photocoagulation control –
The results of the trial, with 3,500 patients, suggested that the cancer came back in around 40% of the patients who took the medicine for five years, as
PPG currently manufactures chlor-alkali and derivates products that are used in many end-use markets, such as paper and pharmaceuticals, purifying drinking water and making bleach. The company intends
MWI is also a distributor of animal health products to veterinarians across the US of America and UK. MWI sells products associated with pharmaceuticals, vaccines, parasiticides, diagnostics, capital
Novartis further intends to collaborate with the Chinese vaccine company for strengthening its vaccines portfolio and pipeline, as well as align production processes and quality standards. Novartis Vaccines
Following the suspension of the agreement, both the companies will retain their businesses and operate independently. Merck and Sanofi-aventis are discontinuing their agreement primarily because of the increasing